Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Ibrutinib With or Without Bortezomib and Dexamethasone for the Treatment of Patients With Relapsed/Refractory Immunoglobulin Light Chain Amyloidosis

NCT03130348 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT03130348
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03130348 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Ibrutinib With or Without Bortezomib and Dexamethasone for the Treatment of Patients With Relapsed/Refractory Immunoglobulin Light Chain Amyloidosis
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Withdrawn
Start date
March 15, 2018
Completion date
April 30, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis, immunoglobulin light chain deposition